- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S1213
| Related Targets | HDAC PARP ATM/ATR DNA-PK WRN Topoisomerase PPAR Sirtuin Casein Kinase eIF |
|---|---|
| Other DNA/RNA Synthesis Inhibitors | B02 CX-5461 (Pidnarulex) SCR7 EED226 Favipiravir (T-705) RK-33 Carmofur Triapine (3-AP) BMH-21 YK-4-279 |
|
In vitro |
DMSO
: 60 mg/mL
(201.83 mM)
Water : 3 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 297.27 | Formula | C11H15N5O5 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 121032-29-9 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | 506U78,Arranon | Smiles | COC1=NC(=NC2=C1N=CN2C3C(C(C(O3)CO)O)O)N | ||
| Features |
Nelarabine is rapidly converted into ara-G through demethoxylation by adenosine deaminase.
|
|---|---|
| Targets/IC50/Ki |
DNA synthesis (PER-255 cells)
67 nM
DNA synthesis (HSB2 cells)
0.44 μM
DNA synthesis (ALL-SIL cells)
1.24 μM
DNA synthesis (JURKAT cells)
2.15 μM
|
| In vitro |
The IC50 of Nelarabine is 25-fold and 113-fold higher than ARAC in T- and B-lineage, respectively. T-ALL cells are eightfold more sensitive to this compound than B-lineage but there is considerable overlap. The efficacy of this chemical in T-lineage and B-lineage cell lines is 25-fold and 113-fold less than ARAC, respectively. It acts by inhibiting DNA synthesis and inducing apoptosis in susceptible cells. This agent demonstrated significant antineoplastic activity with acceptable toxicity.
|
| In vivo |
The Nelarabine plasma AUC is 2.82 mM minutes and the ara-G plasma AUC is 20 mM minutes. The terminal half-life of this compound in plasma is 25 min, clearance is 42 mL/minutes/kg, and central volume of distribution is 1.1 L/kg. The terminal half-life of ara-G in plasma is 182 minutes and the central volume of distribution is 1.4 L/kg. In CSF the terminal half-life of this chemical is 77 minutes and of ara-G is 232 minutes. The AUCcsf:AUCplasma is 29 % for this agent and 23 % for ara-G. This compound and ara-G do not accumulate with daily infusions because of their relatively short half-lives.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT02619630 | Recruiting | T-cell Adult Acute Lymphoblastic Leukemia |
Assistance Publique - Hôpitaux de Paris |
December 2015 | Phase 2 |
| NCT01094860 | Completed | Leukemia |
M.D. Anderson Cancer Center|GlaxoSmithKline |
June 8 2010 | Phase 1 |
| NCT01376115 | Completed | Cancer |
Novartis Pharmaceuticals|Novartis |
January 18 2008 | -- |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.